Nxera Pharma Investor Relations Material
Latest events
Q2 2025
Nxera Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nxera Pharma Co. Ltd
Access all reports
Sosei Group Corporation, also known as Sosei Heptares, is a biopharmaceutical company that specializes in the development of drugs using its proprietary G protein-coupled receptor (GPCR) targeted StaR technology and structure-based drug discovery (SBDD) platform. The company's product lineup includes medicines such as Ultibro, Seebri, Enerzair, Breezhaler, Pivlaz, and Oravi. Sosei Group Corporation is headquartered in Chiyoda-ku, Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.
Key slides for Nxera Pharma Co. Ltd
Q2 2025
Nxera Pharma Co. Ltd
Investor Presentation
Nxera Pharma Co. Ltd
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
4565
Country
🇯🇵 Japan